Semaglutide for the treatment of resistant hypertension

Back

ESC Professional Premium Access

Semaglutide for the treatment of resistant hypertension

Session: Secondary and resistant hypertension

Topic: Pharmacotherapy

Speaker: Doctor C. Kennedy (Dublin, IE)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Cormac Kennedy

Trinity College Dublin, Dublin (Ireland)

1 follower

8 more presentations in this session

Prediction of outcome in malignant hypertension patients using machine learning: a report from the West Birmingham malignant hypertension registry

Speaker: Doctor A. Argyris (Athens, GR)

Ten-year outcomes in patients with hypertension and primary hyperaldosteronism undergoing surgical adrenalectomy versus medical therapy: data from the multinational collaborative network TriNetX

Speaker: Doctor R. Belo Nunes (Sao Paulo, BR)

The effect of spironolactone versus eplerenone on blood pressure targets in resistant hypertension patients.

Speaker: Mrs L. Mishchenko (Kiev, UA)

Cerebral damage after malignant hypertensive crisis: cerebral MRI follow-up data

Speaker: Doctor J. Liegey (Bordeaux, FR)

Impaired systemic microvascular function in patients with resistant arterial hypertension and microalbuminuria: an observational study

Speaker: Doctor E. Tibirica (Rio de Janeiro, BR)

Access the full session

Secondary and resistant hypertension

Speakers: Doctor C. Kennedy, Doctor A. Argyris, Doctor R. Belo Nunes, Mrs L. Mishchenko, Doctor J. Liegey...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources